AVB-620 Publications

Intraoperative Tumor Detection Using a Ratiometric Activatable Fluorescent Peptide: A First-in-Human Phase 1 Study – Ann Surg Oncol. – October 2017

Sensitive in vivo Visualization of Breast Cancer Using Ratiometric Protease-activatable Fluorescent Imaging Agent, AVB-620 – Theranostics – August 2017

Platform Technology

Early detection of squamous cell carcinoma in carcinogen induced oral cancer rodent model by ratiometric activatable cell penetrating peptides – Oral Oncol. – August 2017

Matrix-metalloproteinases in head and neck carcinoma-cancer genome atlas analysis and fluorescence imaging in mice – Otolaryngol Head Neck Surg. – October 2014

Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides – Cancer Res. – January 2013

Ratiometric activatable cell-penetrating peptides provide rapid in vivo readout of thrombin activation – Angew Chem Int Ed Engl – January 2013

Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival – Proc Natl Acad Sci U.S.A – March 2010

Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases – Proc Natl Acad Sci U.S.A – March 2010

In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancerIntegr Biol (Camb) – June 2009

Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides – Integr Biol (Camb) – June 2009

Tumor imaging by means of proteolytic activation of cell-penetrating peptides – Proc Natl Acad Sci U.S.A – December 2004